NRx Pharmaceuticals, Inc. logo

NRx Pharmaceuticals, Inc. (NRXP)

Market Open
11 Sep, 15:26
NASDAQ (CM) NASDAQ (CM)
$
3. 40
0
0%
$
59.98M Market Cap
- P/E Ratio
- Div Yield
132,462 Volume
0 Eps
$ 3.4
Previous Close
Add Transaction
Day Range
3.37 3.44
Year Range
1.62 5.05
Want to track NRXP and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
NRx Pharmaceuticals, Inc. (NRXP) Q4 2024 Earnings Call Transcript

NRx Pharmaceuticals, Inc. (NRXP) Q4 2024 Earnings Call Transcript

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP ) Q4 2024 Earnings Conference Call March 17, 2025 8:30 AM ET Company Participants Matthew Duffy - Chief Business Officer Jonathan Javitt - Founder, Chairman and Chief Scientist Michael Abrams - Chief Financial Officer Conference Call Participants Jason Kolbert - D. Boral Capital Thomas Shrader - BTIG Vernon Bernardino - H.C.

Seekingalpha | 1 year ago
NRx Pharmaceuticals to Post Q4 Earnings: How to Play the Stock?

NRx Pharmaceuticals to Post Q4 Earnings: How to Play the Stock?

NRXP is expected to provide updates on its pipeline candidates being developed for treating central nervous system disorders when it reports fourth-quarter earnings release.

Zacks | 1 year ago
Best Momentum Stocks to Buy for January 6th

Best Momentum Stocks to Buy for January 6th

NRXP, PDEX and PBYI made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 6, 2024.

Zacks | 1 year ago
NRx Pharmaceuticals (NRXP) Upgraded to Buy: Here's Why

NRx Pharmaceuticals (NRXP) Upgraded to Buy: Here's Why

NRx Pharmaceuticals (NRXP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks | 1 year ago
NRx Pharmaceuticals, Inc. (NRXP) Q3 2024 Earnings Call Transcript

NRx Pharmaceuticals, Inc. (NRXP) Q3 2024 Earnings Call Transcript

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP ) Q3 2024 Earnings Conference Call November 18, 2024 4:30 PM ET Company Participants Matthew Duffy - Chief Business Officer Jonathan Javitt - Founder, Chairman and Chief Scientist Richard Narido - Interim Chief Financial Officer and Treasurer Michael Abrams - Incoming Chief Financial Officer Conference Call Participants Jason Kolbert - D. Boral Capital Ed Woo - Ascendiant Vernon Bernardino - H.C.

Seekingalpha | 1 year ago
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) and HOPE Therapeutics, Inc. Announce Participation at the ThinkEquity Conference October 30, 2024

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) and HOPE Therapeutics, Inc. Announce Participation at the ThinkEquity Conference October 30, 2024

MIAMI, FL., October 23, 2024 – PRISM MediaWire – NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, (“NRx,” the “Company”) and HOPE Therapeutics, Inc.

Prismmediawire | 1 year ago
NRx Pharmaceuticals, Inc. (NRXP) Q2 2024 Earnings Call Transcript

NRx Pharmaceuticals, Inc. (NRXP) Q2 2024 Earnings Call Transcript

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP ) Q2 2024 Earnings Conference Call August 14, 2024 4:30 PM ET Company Participants Matthew Duffy - Chief Business Officer Dr. Jonathan Javitt - Founder, Chairman and Chief Scientist Stephen Willard - Chief Executive Officer Richard Narido - Chief Financial Officer and Treasurer Conference Call Participants Ed Woo - Ascendiant Operator Good afternoon, everyone. And welcome to the NRx Pharmaceuticals Incorporated Second Quarter of 2024 Results Conference Call.

Seekingalpha | 2 years ago